Neostigmine

Cholinesterase Inhibitor — NERVOUS SYSTEM

Key facts

Neostigmine is an ofp drug in the Cholinesterase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2013. Its mechanism of action is classified as Cholinesterase Inhibitors. DrugCentral lists 6 molecular targets, including ache, ACHE and Ache. Recorded indications include Myasthenia gravis, Retention of urine and Reversal of neuromuscular blockade.

• Approval status: ofp (first approved 2013 by the FDA).
• Drug class: Cholinesterase Inhibitor.
• Mechanism of action: Cholinesterase Inhibitors.
• Molecular targets: ache, ACHE, Ache and BCHE (6 listed in DrugCentral).
• Indications: Myasthenia gravis, Retention of urine and Reversal of neuromuscular blockade.
• ATC code: N07AA01 (Anticholinesterases).
• Molecular formula: C12H19N2O2; molecular weight 223.29 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Myasthenia gravis
• Retention of urine
• Reversal of neuromuscular blockade

Contraindications (15)

• Asthma
• Colonic Necrosis
• Conduction disorder of the heart
• Coronary occlusion
• Gastrointestinal hypomotility
• Gastrointestinal obstruction
• Hyperthyroidism
• Increased Bronchial Secretions
• Increased gastric tonus
• Macrocolon
• Peptic ulcer
• Peritonitis
• Seizure disorder
• Sinus bradycardia
• Urinary tract obstruction

Mechanism & targets

• Mechanism of action (MoA): Cholinesterase Inhibitors
• Established pharmacologic class: Cholinesterase Inhibitor

Molecular targets (6)

Target	Gene	Action	Activity
Acetylcholinesterase	ache	unknown	IC50 8.34
Acetylcholinesterase	ACHE	inhibitor	IC50 7.59
Acetylcholinesterase	Ache	unknown	IC50 7.46
Cholinesterase	BCHE	unknown	IC50 7.22
Cholinesterase	BCHE	unknown	IC50 7.15
Acetylcholinesterase	ache	unknown	Ki 6.00

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2013-05-31	FDA	—	ECLAT PHARMS LLC

ATC classification

ATC code	Therapeutic hierarchy
N07AA01	NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › PARASYMPATHOMIMETICS › Anticholinesterases
N07AA51	NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › PARASYMPATHOMIMETICS › Anticholinesterases
S01EB06	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIGLAUCOMA PREPARATIONS AND MIOTICS › Parasympathomimetics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Serotonin syndrome	187.2
Cardiac arrest	142.1
Bradycardia	138.4
Neuromuscular block prolonged	102.1
Vascular encephalopathy	94.7
Drug interaction	85.7
Subileus	81.4
Pulmonary oedema	76.7
Hypotension	71.9
Post procedural complication	70.7
Cerebral haemorrhage foetal	70.3
Schizencephaly	69.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Neostigmine is on its molecule page.

• Molecular formula: C₁₂H₁₉N₂O₂
• Molecular weight: 223.29 g/mol
• CAS number: 59-99-4
• InChIKey: ALWKGYPQUAPLQC-UHFFFAOYSA-N
• PubChem CID: 4456

CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Neostigmine used for?

DrugCentral lists the following indications for Neostigmine: Myasthenia gravis, Retention of urine and Reversal of neuromuscular blockade.

How does Neostigmine work?

Neostigmine is classified as Cholinesterase Inhibitors; its molecular targets in DrugCentral include ache, ACHE (inhibitor), Ache and BCHE.

When was Neostigmine first approved?

Neostigmine was first approved by the FDA in 2013.

What drug class does Neostigmine belong to?

Neostigmine is in the Cholinesterase Inhibitor class.

What is the chemical formula of Neostigmine?

Neostigmine has the molecular formula C12H19N2O2 and a molecular weight of 223.29 g/mol.

Sources

• DrugCentral drug card 1897 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL211471 — compound record and bioactivity
• PubChem CID 4456 — chemical identifiers
• DrugBank DB01400 — drug record
• FDA UNII 3982TWQ96G — substance identity
• DailyMed: FDA labels for Neostigmine — current prescribing information (label search)
• UniProt P22303 (ACHE) — target protein
• UniProt P06276 (BCHE) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.